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Abstract 
We identified a novel SETD1B/GTF2H3 fusion 
gene in a polycythemia vera (PV) patient with 
complex karyotype, harboring a cryptic deletion 
involving chromosome band 12q24.31. This 
rearrangement led to the juxtaposition of the 
SETD1B (SET domain containing 1B) gene at intron 
11 (chr12:122,257,801) with the GTF2H3 (general 
transcription factor IIH, polypeptide 3) gene at intron 
5 (chr12:124,137,254). In silico translation showed 
a protein retaining SETD1B RNA binding domain 
(RRM_S) at its N-terminus and a portion of GTF2H3 
DNA binding domain (Tfb4) at its C-terminus. We 
also provided evidences that SETD1B might be 
rearranged in an additional PV case, although in a 
small proportion of hematopoietic cells, indicating a 
possible role of SETD1B in disease pathogenesis. 
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Disease 
Polycythemia Vera 
Note 
Myeloproliferative neoplasm 
Phenotype/cell stem origin 
CD34+ cell 
Etiology 
SETD1B is a SET-domain containing protein with 
histone H3-Lys4 methyltransferase activity, which is 
associated with active gene expression (Lee et al. 
2007).  
SET-like enzyme genes include those implicated in 
various leukemias and cancers like MLL. SETD1B 
interacts with RBM15 through its LSD motif, 
creating a complex important for epigenetic 
regulation (Lee et al. 2002). RBM15 (RNA binding 
motif protein 15) utilizes the epigenetic mechanism 
to control alternative splicing of MPL 
(myeloproliferative leukemia virus oncogene), 
leading to the regulation of thrombopoietin response 
in hematopoietic stem cells (Xiao et al. 2014).  
In the SETD1B/GTF2H3 chimeric protein, SETD1B 
loses the LSD domain, possibly leading to an altered 
epigenetic regulation. GTF2H3 has been related to 
the nucleotide excision repair pathway, and resulted 
upregulated in HL-60 cell line resistant to ATRA 
(Liu et al. 2014). 
Epidemiology 
The SETD1B/GTF2H3 rearrangement was found in 
only one out of 60 patients with myeloproliferative 
neoplasms evaluated. However, FISH analysis 
revealed a splitting signal in a very low percentage 
of nuclei (3/412, 0.7%) in one of 13 analyzed 
patients, suggesting a possible rearrangement of 
SETD1B with other partner genes (Storlazzi et al. 
2014). 
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Partial karyotype of the patient with del(12) (lower panel), showing FISH analysis performed by using three BAC clones 
encompassing the SETD1B gene region (upper panel). The colored rectangles (blue, red, and green) correspond to the results 
obtained respectively for probes RP11-1065O14, RP11-7M8, and RP11-87C12. The deletion breakpoint in the patient was 
mapped within RP11-7M8, as its signal intensity on the deleted chromosome 12 [del(12)] was significantly fainter than the one on 
the normal homolog. RP11-1066D14 was retained on del(12), while RP11-87C12 was deleted on del(12). 
 
Clinics 
The SETD1B/GTF2H3 rearrangement has been 
found in a patient diagnosed with Polycythemia Vera 
that evolved in post-polycythemia vera 
myelofibrosis after two years. 
Cytology 
Blood smear showed no leukoerythroblastic picture 
but only few dacrocytes. 
Pathology 
The bone marrow biopsy showed the presence of 
hyperplasia of myeloid and erythroid lineages, 
increased scattered megakaryocytes without overt 
morphologic abnormalities and an increase in 
reticulin fibrosis compatible with grade 1 of 3 
(european scale). 
Treatment 
The subject was treated with phlebotomies and 
hydroxyurea according to the European Leukemia 
Net (ELN) recommendations (Barbui et al. 2011), 
but considered as refractory/resistant to hydroxyurea 
(Barosi et al. 2010). The patient was then enrolled in 
a clinical trial with the histone deacethylase inhibitor 
givinostat, obtaining prompt relief from pruritus and 
rapid reduction up to stop of phlebotomies (Finazzi 
et al. 2013). However, the treatment was interrupted 
after six months because of progression of a pre-
existing mild renal insufficiency, and the subject was 
shifted again to low-dose hydroxyurea plus 
phlebotomies. 
Evolution 
Two years after the detection of the 
SETD1B/GTF2H3 fusion gene, the patient was 
diagnosed with post polycythemia vera 
myelofibrosis according to the diagnostic criteria of 
the International Working Group for 
Myeloproliferative Disorders Research and 
Treatment (IWG-MRT) (Barosi et al, 2008). At that 
time, the gene fusion was still detectable in bone 
marrow sample. 
Cytogenetics 
Note 
The rearrangement leading to the genesis of this 
fusion gene (a cryptic deletion on chromosome 12) 
was not evident at cytogenetic level. 
Cytogenetics morphological 
The only described PV patient harboring this novel 
fusion gene showed a complex karyotype. 
Cytogenetics molecular 
The SETD1B/GTF2H3 fusion gene was identified 
by genomic massive sequencing. FISH analysis with 
an appropriate probe set for SETD1B disclosed the 
occurrence of a 110Kb interstitial deletion, 
confirming the gene rearrangement. 
Additional anomalies 
A ins(6;15) insertion accompanied by chromosome 
losses at all the breakpoint regions [6p22.1p22.3  
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Wild-type SETDB1 (grey), GTF2H3 (blue) and chimeric SETD1B/GTF2H3 predicted proteins, accordingly to ORF finder and 
BlastP analyses of the full-length transcripts. Red arrows indicate the breakpoints, respectively in SETD1B (Accession no. 
NP_055863, aminoacid no.1260), and in GTF2H3 (Accession no. NP_001507, aminoacid no.153). RRM_S: RNA recognition 
motif; N-SET, SET: catalytic domains for H3K4 trimethylation; P: cystein-rich motif; TBF4: transcription factor with DNA binding 
domain. 
(11,6 Mb), 15q21.3q22.2 (6 Mb), and 15q25.1q25.2 
(3 Mb)]; a cryptic and inverted insertion of a short 
chromosome 15q25.1 fragment (chr15:79,476,511-
79,486,994) into chromosome 18, accompanied by a 
25.7 Kb heterozygous deletion 
Genes involved and 
proteins 
SETD1B 
Location 
12q24.31 (chr12:122,242,638-122,270,562) 
DNA/RNA 
Homo sapiens SET domain containing 1B (SETD1B 
Protein 
SET1B is a component of a histone 
methyltransferase complex that produces 
trimethylated histone H3 at Lys4. 
GTF2H3 
Location 
12q24.31 (chr12:124,118,286-124,147,151) 
DNA/RNA 
Homo sapiens general transcription factor IIH, 
polypeptide 3. The gene encodes for four transcript 
variants. 
Protein 
GTF2H3 is a subunit of the core-TFIIH basal 
transcription factor. It localizes to the nucleus and is 
involved in RNA transcription and nucleotide 
excision repair. Moreover, it associates with the 
Cdk-activating kinase complex. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
5' SETD1B/3' GTF2H3. SETD1B (accession no. 
NM_015048) at exon 11 was fused in frame with  
 
GTF2H3 (accession no. NM_001516) at exon 7. 
Detection 
Genomic paired-end massive sequencing.  
The fusion transcript was validated by RT-PCR and 
Sanger sequencing. 
Fusion protein 
Description 
In silico translation of the fusion transcript, obtained 
by ORF finder, showed a putative protein 
maintaining the SETD1B RNA binding domain 
(RRM_S) at its N-terminus and a portion of GTF2H3 
DNA binding domain (Tfb4) at its C-terminus 
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